NCT01971606View on ClinicalTrials.gov

Impact of High-dose Pretreatment of Rosuvastatin in Patients With Acute Coronary Syndrome Following Off-pump Coronary Artery Bypass: Results From the HIROP-ACS (HIgh-dose Pretreatment of Rosuvastatin During Off-Pump Coronary Bypass in Acute Coronary Syndrome) Study

PHASE4CompletedINTERVENTIONAL

Enrollment

234

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

June 30, 2012

Study Completion Date

March 31, 2013

Conditions

A Total of 234 Patients With Acute Coronary Syndrome Who Will Undergo OPCAB.

Interventions

DRUG

Rosuvastatin

"Patients will be randomized in a ratio of 1:1 to A) High-dose rosuvastatin vs. B) Placebo.~A) Rosuvastatin group : Administration of 40mg of rosuvastatin PO 12 hours before surgery and 20mg of rosuvastatin PO 2hours before surgery and 10mg of rosuvastatin PO daily at postoperative period.~B) Placebo group : Administration of placebo at 12 hours and 2 hours before surgery and 10mg of rosuvastatin PO daily at postoperative period."

Trial Locations (1)

120-752

Division of Cardiovascular Surgery, Severance Cardiovascular Hospital , Yonsei University College of Medicine, Seoul

All Listed Sponsors

lead

Yonsei University

OTHER